RAC 4.32% $1.55 race oncology ltd

Ann: Race Leadership Changes, page-339

  1. 2,710 Posts.
    lightbulb Created with Sketch. 2824
    I am sure it will be the same. The untenable difference said with “some” board members. if it relates to science CSO imo should have the final say. If commercial then board majority. Was it under the radar, partner timing, cardio v FTO priority, capital raise and dilution, or combination, something else. We may never know…
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.